Tag Archives: Novartis
By William Looney | Published: April 3, 2013
Monday’s decision by India’s Supreme Court to deny a patent for the top-selling oncologic drug Glivec took nearly a decade of litigation to resolve – but the implications in and beyond India are both immediate and lasting. Here’s a list of six that Pharm Exec thinks are most important:
By Guest Blogger | Published: February 4, 2013
By Stephanie Sutton. The European Commission claims that Johnson & Johnson and Novartis may have breached European antitrust rules.
By Guest Blogger | Published: October 31, 2012
By Jennifer Markarian Pharmaceutical industry leaders Novartis and Merck—among others—released second-quarter 2012 results showing global sales down in third-quarter 2012, with growth in key pharmaceutical products helping to offset losses due to patent expirations.
By Ben Comer | Published: May 21, 2012
Recognizing that traditional market forces – namely incentives related to intellectual property and a steady demand for products – have failed in developing countries, the World Health Organization (WHO) asked a member state-nominated group to come up with ways to fund R&D and pay for the treatment of neglected diseases in the world’s poorest nations. [...]
By Guest Blogger | Published: March 20, 2012
By Ana Nicholls, Healthcare Analyst at the Economist Intelligence Unit. The UK Financial Times this week (March 18) flagged up data from Withers & Rogers, a London-based IP firm, showing how the numbers of patent filings from the ten leading pharma companies has dropped in recent years. According to the law firm, only 129 “patent families” [...]